1. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Issue 10 (October 2019) Authors: Motzer, Robert J; Rini, Brian I; McDermott, David F; Arén Frontera, Osvaldo; Hammers, Hans J; Carducci, Michael A; Salman, Pamela; Escudier, Bernard; Beuselinck, Benoit; Amin, Asim; Porta, Camillo; George, Saby; Neiman, Victoria; Bracarda, Sergio; Tykodi, Scott S; Barthélémy, Philippe; Leibowitz-... Journal: Lancet oncology Issue: Volume 20:Issue 10(2019) Page Start: 1370 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗